Salix, Santarus report robust revenue growth ahead of merger

Salix Pharmaceuticals (SLXP) reports revenue growth of 29% for Q3.

Revenue by product: Xifaxan, +20% to $165.9M; Apriso, +93% to $38.1M; Relistor, $4.3M; Moviprep, $19.2M; Solesta, $1.8M; Deflux, $6.6M.

Xifaxan prescription growth: 24% Y/Y.

FY13 outlook: Revenue of $920M (unchanged). Non-GAAP EPS of $3.20. (PR)

Q3 revenues jump 81% Y/Y for Santarus (SNTS), while non-GAAP earnings rise 189%.

Revenue by product: Glumetza, $45.6M; Zegerid, $27.1M; Uceris, $19.6M; Cycloset, $4.2M; Fenoglide, $1.6M. (PR)

See also: SLXP, SNTS talk synergies, diversification; 2014 guidance provided

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs